Trial record 4 of 5 for:    evp-6124, schizophrenia

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by FORUM Pharmaceuticals Inc
Sponsor:
Collaborator:
INC Research
Information provided by (Responsible Party):
FORUM Pharmaceuticals Inc
ClinicalTrials.gov Identifier:
NCT01714713
First received: October 19, 2012
Last updated: February 25, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)